Join the Oncology Voice Network. Join for Free
Why is it so hard to get into oncology
oncology MSL oncology medical science liaison breaking into oncology oncology career advice MSL best practices conference

Why is it so hard to get into oncology


Share This Article


Summary

In this episode, Mary Miao shares her journey and experiences in the oncology field, offering insights into the unique challenges and strategies for breaking into this specialized area. Mary discusses the distinctions between oncology and other therapeutic areas, providing valuable advice for aspiring oncology MSLs. She emphasizes the importance of networking within the oncology community, preparing effectively for MSL roles, and making applications stand out. Mary also highlights the significance of documenting work, maintaining a strong CV, and leveraging LinkedIn for networking. The episode concludes with Mary's advice on embracing humility and continuous learning, along with a promotion for the MSL best practices conference.

My guest today is Mary Miao, Oncology Medical Science Liaison with Immunogen. Mary shares insights on why it is so hard to get into oncology.

This episode is sponsored by Momentum Events and the 2nd MSL Best Practices Summit, virtual event on September 14-15. For more info: https://momentumevents.com/msl-bestpractices/

Mary discusses…

👉 Why there is so much interest in oncology
👉 Why it is difficult to get into the oncology space
👉 How oncology is different from other Therapeutic Areas
👉 What someone needs to do to get into an oncology position
👉 How to prepare yourself to make a successful transition once you're in

Click for Source
oncology MSL, oncology medical science liaison, breaking into oncology, oncology career advice, MSL best practices conference

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How will COVID-19 affect the MSL role and what new skills may emerge as necessary to maintain value, access and future succes
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How will COVID-19 affect the MSL role and what new skills may emerge as necessary to maintain value, access and future succes

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Where Did My Interview Go Wrong?
Partner Avatar Tom Caravela

Where Did My Interview Go Wrong?

Explore OVN